Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

被引：266

作者：

Cafaro, A

Caputo, A

Fracasso, C

Maggiorella, MT

Goletti, D

Baroncelli, S

Pace, M

Sernicola, L

Koanga-Mogtomo, ML

Betti, M

Borsetti, A

Belli, R

Åkerblom, L

Corrias, F

Buttò, S

Heeney, J

Verani, P

Titti, F

Ensoli, B

机构：

[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy

[2] Univ Ferrara, Dept Exp & Diagnost Med, I-44100 Ferrara, Italy

[3] Natl Vet Inst, Dept Virol, Biomed Ctr, S-75183 Uppsala, Sweden

[4] Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk ZH, Netherlands

来源：

NATURE MEDICINE | 1999年 / 5卷 / 06期

关键词：

D O I：

10.1038/9488

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4(+) T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.

引用

页码：643 / 650

页数：8

共 58 条

[1]

ALMOND NM, 1998, AIDS, V12, P133

[2]

Ando K, 1997, J IMMUNOL, V158, P5283

[3] TRANS-ACTIVATOR GENE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-III (HTLV-III) [J].